Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChondroStem
- Development stage
- Preclinical
- Lead developer
- International Stem Cell Corporation
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
ChondroStem is a cell therapy product developed by International Stem Cell Corp. for the treatment of musculoskeletal and skin diseases, with a primary focus on osteoarthritis. It is classified as a stem cell-based therapy, specifically designed to address cartilage degeneration and joint disorders. The mechanism of action likely involves the use of stem cells to promote regeneration or repair of damaged cartilage tissue in affected joints, although detailed mechanistic data are not publicly available. As of May 2025, ChondroStem's highest reported development status is preclinical, with no regulatory approvals or completed clinical trials disclosed[4].
- Brand names
- ChondroStem
Beyond the preview
Go deeper on ChondroStem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChondroStem.